Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.9 kDa. The protein migrates as 42-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus FGFR2 (IIIb), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Cynomolgus FGFR2 (IIIb), His Tag (Cat. No. FGB-C52H6) is more than 90% and the molecular weight of this protein is around 34-51 kDa verified by SEC-MALS.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Thyroid Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Stromal Tumors; Hepatic Insufficiency; Bone Neoplasms; Endometrial Neoplasms; Gallbladder Neoplasms; Fallopian Tube Neoplasms; Medullary thyroid cancer (MTC); Sarcoma, Alveolar Soft Part; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Melanoma; Osteoma; Gastroenteropancreatic neuroendocrine tumor; Small Cell Lung Carcinoma; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Leiomyosarcoma; Esophageal Neoplasms; Stomach Neoplasms; Thoracic Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neuroendocrine Tumors; Sarcoma, Synovial; Liver Diseases; Sarcoma; Bile Duct Diseases; Nasopharyngeal Carcinoma | Details |
Lenvatinib Mesylate | MK-7902; ER-203492-00; E-7080 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Neuroendocrine Tumors; Paraganglioma; Thyroid Cancer, Papillary; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Carcinoma, Adenoid Cystic; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Neoplasms; Renal Insufficiency; Pheochromocytoma; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Liver Neoplasms; Biliary Tract Neoplasms | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Leukemia, Myeloid, Acute; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Thyroid Neoplasms; Fallopian Tube Neoplasms; Osteosarcoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Neoplasm Metastasis; Adenocarcinoma; Somatostatinoma; Gastrointestinal Neoplasms; Melanoma; Meningioma; Neoplasms; Solid tumours; Liver Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Insulinoma; Carcinoma, Islet Cell; Hemangiosarcoma; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Gastrinoma; Sarcoma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
Futibatinib | TAS-120 | Approved | Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Central Nervous System Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Endometrial Neoplasms; Lymphoma; Metastatic breast cancer; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Esophageal Neoplasms; Carcinoma; Stomach Neoplasms; Bone Marrow Neoplasms; Solid tumours | Details |
Selpercatinib | ARRY-192; Ret-IN-1; LOXO-292; LY-3527723 | Approved | Array Biopharma | Retevmo, Retsevmo | United States | Medullary thyroid cancer (MTC); Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms | Loxo Oncology Inc | 2020-05-08 | Medullary thyroid cancer (MTC); Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Thyroid Neoplasms; Hepatic Insufficiency; Neuroblastoma; Histiocytosis, Langerhans-Cell; Sarcoma, Ewing; Osteosarcoma; Fibrosarcoma; Sarcoma; Myofibromatosis; Wilms Tumor; Neoplasms; Thyroid Carcinoma, Anaplastic; Colonic Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Renal Insufficiency; Medulloblastoma; Ependymoma; Rhabdomyosarcoma; Hematologic Neoplasms; Solid tumours | Details |
Pemigatinib | INCB-054828; INCB-54828; IBI-375 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | United States | Cholangiocarcinoma | Incyte Corp | 2020-04-17 | Cholangiocarcinoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Lymphoma, Non-Hodgkin; Glioma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Urologic Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Colitis, Ulcerative; Translocation, Genetic; Breast Neoplasms; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Transitional Cell; Myeloproliferative Disorders; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Solid tumours; Bone Marrow Neoplasms | Details |
Tasurgratinib | E-7090 | Approved | Eisai Co Ltd | TASFYGO | Japan | Biliary Tract Neoplasms | Eisai Co Ltd | 2024-09-24 | Biliary Tract Neoplasms; Solid tumours; Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency | Details |
Erdafitinib | 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 | Approved | Astex Pharmaceuticals Inc | Balversa, 博珂 | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Carcinoma, Squamous Cell; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Sarcoma; Glioma; Metastatic breast cancer; Carcinoma, Neuroendocrine; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Adenocarcinoma; Hepatoblastoma; Ependymoma; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Bone metastases; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Rhabdoid Tumor; Solid tumours; Glioblastoma; Carcinoma, Transitional Cell; Neoplasms; Wilms Tumor; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Prostatic Neoplasms, Castration-Resistant; Histiocytosis, Langerhans-Cell | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bemarituzumab | FPA-144 | Phase 3 Clinical | Five Prime Therapeutics Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Rogaratinib | BAY-1163877 | Phase 3 Clinical | Bayer AG | Solid tumours; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
Infigratinib | BGJ-398; NVP-BGJ398 | Phase 3 Clinical | Novartis Pharma Ag | Pancreatic Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Glioma; Gastrointestinal Stromal Tumors; Oropharyngeal Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Central Nervous System Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Biliary Tract Neoplasms; Glioblastoma; Achondroplasia; Papillomavirus Infections; Neoplasms; Nasopharyngeal Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Solid tumours | Details |
SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Zoligratinib | CH-5183284; FF-284; Debio-1347 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours; Breast Neoplasms | Details |
AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Ovarian Neoplasms; Liver Neoplasms; Kidney Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Solid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Genital Neoplasms, Female; Colorectal Neoplasms; Thymus Neoplasms; Lung Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Fexagratinib | AZD4547; AZD-4547; ABSK-091; ABSK091 | Phase 2 Clinical | Astrazeneca Plc | Lymphoma; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Glioma; Uterine Neoplasms; Urinary Bladder Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Metastatic breast cancer; Melanoma; Carcinoma, Non-Small-Cell Lung; Foodborne Diseases; Adenocarcinoma; Uterine Cervical Neoplasms; Rectal Neoplasms; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Gastrointestinal Diseases; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Renal Cell; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Skin Neoplasms | Details |
Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms; Carcinoma, Hepatocellular | Details |
HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 2 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours; Cholangiocarcinoma | Details |
3HP-2827 | 3HP-2827; 3HP2827 | Phase 2 Clinical | 3H (Suzhou) Pharmaceuticals Co Ltd | Solid tumours; Neoplasms | Details |
CGT-4859 | CGT4859; CGT-4859 | Phase 2 Clinical | Cogent Biosciences Inc | Solid tumours; Neoplasms; Cholangiocarcinoma | Details |
HMPL-453 | HMPL-453 | Phase 2 Clinical | Hutchison Medipharma Ltd | Solid tumours; Biliary Tract Neoplasms; Neoplasms, Mesothelial; Mesothelioma; Cholangiocarcinoma | Details |
ABSK-061 | ABSK061 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours; Esophageal Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
Lirafugratinib | RLY-4008 | Phase 2 Clinical | Relay Therapeutics Inc | Solid tumours; Translocation, Genetic; Cholangiocarcinoma | Details |
PZH-2111 | PZH2111; PZH-2111 | Phase 2 Clinical | Zhangzhou Pientzehuang Pharmaceutical Co Ltd | Solid tumours; Cholangiocarcinoma | Details |
Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms | Details |
BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
TYRA-200 | TYRA200; TYRA-200 | Phase 1 Clinical | Tyra Biosciences Inc | Solid tumours; Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms | Details |
Resigratinib | KIN-3248; KIN-003 | Phase 1 Clinical | Kinnate Biopharma Inc | Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Cholangiocarcinoma | Details |
BG-C137 | BG-C137 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours; Gastrointestinal Neoplasms | Details |
ACE-16229210 | ACE-16229210; ACE16229210 | Phase 1 Clinical | Acerand Therapeutics (Shanghai) Ltd | Solid tumours | Details |
MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
TT-00434 | TT-00434 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
ABSK-121 | ABSK121-NX; ABSK121 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
LY-2874455 | LY-2874455 | Phase 1 Clinical | Eli Lilly And Company | Neoplasms; Leukemia, Myeloid, Acute | Details |
CPL-304110 | CPL-304110; CPL-304-110 | Phase 1 Clinical | Celon Pharma Sa | Stomach Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Sarcoma; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.